| Outpatient transfusions for myelodysplastic syndromes |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Genetic predisposition to MDS: diagnosis and management |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Targeting TP53 Mutations in Myelodysplastic Syndromes |
|
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
| Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes |
|
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes |
|
Hematology/oncology and stem cell therapy |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology |
|
Histopathology |
Myelodysplastic Syndromes (MDS) |
| Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
|
Immunotherapy |
Aplastic Anemia |
| VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases |
|
Internal and Emergency Medicine |
Myelodysplastic Syndromes (MDS) |
| High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity |
|
International Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| High Serum Ferritin Levels in Newly Diagnosed Patients With Myelodysplastic Syndromes Are Associated With Greater Symptom Severity |
|
International Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
